BACKGROUND: The aim of this study was to investigate whether focal adhesion kinase (FAK) overexpression correlates with lymph node metastases and prognosis. METHODS: The protein expression of FAK was investigated in 153 paraffin-embedded tissues by immunohistochemical analysis and then correlated with various clinicopathologic parameters. FAK mRNA level was detected with quantitative RT-PCR in 57 NSCLC frozen tissues and 20 normal matched tissues. RESULTS: Immunohistochemistry showed FAK overexpression was significantly associated with positive lymph node metastasis and more advanced disease stage of NSCLCs and adenocarcinoma subtype; real-time PCR also indicated a statistically significant correlation between increased FAK mRNA level and the presence of nodal metastases. Moreover, in survival analysis, FAK overexpression was significantly associated with worse overall survival. CONCLUSIONS: FAK overexpression is a promising pathological factor to predict aggressive behavior and prognosis in patients with NSCLC, particularly in the adenocarcinoma subtype.
BACKGROUND: The aim of this study was to investigate whether focal adhesion kinase (FAK) overexpression correlates with lymph node metastases and prognosis. METHODS: The protein expression of FAK was investigated in 153 paraffin-embedded tissues by immunohistochemical analysis and then correlated with various clinicopathologic parameters. FAK mRNA level was detected with quantitative RT-PCR in 57 NSCLC frozen tissues and 20 normal matched tissues. RESULTS: Immunohistochemistry showed FAK overexpression was significantly associated with positive lymph node metastasis and more advanced disease stage of NSCLCs and adenocarcinoma subtype; real-time PCR also indicated a statistically significant correlation between increased FAK mRNA level and the presence of nodal metastases. Moreover, in survival analysis, FAK overexpression was significantly associated with worse overall survival. CONCLUSIONS:FAK overexpression is a promising pathological factor to predict aggressive behavior and prognosis in patients with NSCLC, particularly in the adenocarcinoma subtype.
Authors: Gordon W McLean; Neil O Carragher; Egle Avizienyte; Jeff Evans; Valerie G Brunton; Margaret C Frame Journal: Nat Rev Cancer Date: 2005-07 Impact factor: 60.716
Authors: X N Meng; Y Jin; Y Yu; J Bai; G Y Liu; J Zhu; Y Z Zhao; Z Wang; F Chen; K-Y Lee; S B Fu Journal: Br J Cancer Date: 2009-06-30 Impact factor: 7.640
Authors: Donghang Zheng; Vita Golubovskaya; Elena Kurenova; Cheng Wood; Nicole A Massoll; David Ostrov; William G Cance; Steven N Hochwald Journal: Mol Carcinog Date: 2010-02 Impact factor: 4.784
Authors: Grace K Dy; Lourdes Ylagan; Saraswati Pokharel; Austin Miller; Elizabeth Brese; Wiam Bshara; Carl Morrison; William G Cance; Vita M Golubovskaya Journal: J Thorac Oncol Date: 2014-09 Impact factor: 15.609
Authors: Scott A Gunn; Lauren M Kreps; Huijun Zhao; Katelyn Landon; Jacob S Ilacqua; Christina L Addison Journal: J Bone Oncol Date: 2022-05-13 Impact factor: 4.491
Authors: Delphine M Lees; Louise E Reynolds; Ana Rita Pedrosa; Marina Roy-Luzarraga; Kairbaan M Hodivala-Dilke Journal: Angiogenesis Date: 2021-03-17 Impact factor: 10.658
Authors: Annika N Alexopoulou; Colan M Ho-Yen; Vassilis Papalazarou; George Elia; J Louise Jones; Kairbaan Hodivala-Dilke Journal: BMC Cancer Date: 2014-04-02 Impact factor: 4.430